Monte Rosa Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 135.35 million compared to USD 108.5 million a year ago. Basic loss per share from continuing operations was USD 2.63 compared to USD 2.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | +0.50% | -4.31% | -29.20% |
May. 30 | Monte Rosa Therapeutics Names Three Insiders to Leadership Team | MT |
May. 30 | Monte Rosa Therapeutics, Inc. Announces Executive Promotions | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.20% | 245M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023